Key statistics
On Friday, Microbot Medical Inc (CY9D:BER) closed at 0.8585, 20.49% above the 52 week low of 0.7125 set on Sep 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8585 |
---|---|
High | 0.8585 |
Low | 0.8585 |
Bid | 0.9265 |
Offer | 0.9675 |
Previous close | 0.869 |
Average volume | 967.90 |
---|---|
Shares outstanding | 16.50m |
Free float | 16.69m |
P/E (TTM) | -- |
Market cap | 16.83m USD |
EPS (TTM) | -0.81 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
- Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
- Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
- Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
- Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
- Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
- Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
- Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
- Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
- Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
- Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
More ▼